Table 1.
Characteristics of 512 447 women given a diagnosis of early breast cancer in England during 1993-2015.
| Characteristic | No (%) women by calendar period of diagnosis | ||||
|---|---|---|---|---|---|
| 1993-99 (n=113 354; 16 193/year) | 2000-04 (n=114 826; 22 965/year) | 2005-09 (n=127 929; 25 586/year) | 2010-15 (n=156 338; 26 056/year) | All years (n=512 447; 22 280/year) | |
| Age at diagnosis, years*: | |||||
| 18-39 | 7852 (7) | 7002 (6) | 6552 (5) | 6717 (4) | 28 123 (5) |
| 40-49 | 21 718 (19) | 19 313 (17) | 22 369 (17) | 27 908 (18) | 91 308 (18) |
| 50-64 | 47 465 (42) | 50 761 (44) | 53 741 (42) | 62 074 (40) | 214 041 (42) |
| 65-70 | 13 385 (12) | 14 399 (13) | 20 207 (16) | 27 419 (18) | 75 410 (15) |
| 71-79 | 16 988 (15) | 16 703 (15) | 17 122 (13) | 21 972 (14) | 72 785 (14) |
| 80-89 | 5946 (5) | 6648 (6) | 7938 (6) | 10 248 (7) | 30 780 (6) |
| Cancer screen detected: | |||||
| Eligible—screen detected | 14 981 (13) | 20 190 (18) | 41 272 (32) | 51 797 (33) | 128 240 (25) |
| Eligible—not screen detected | 32 484 (29) | 30 571 (27) | 32 676 (26) | 37 696 (24) | 133 427 (26) |
| Not eligible for screening | 65 889 (58) | 64 065 (56) | 53 981 (42) | 66 845 (43) | 250 780 (49) |
| Tumour size, mm†: | |||||
| 1-20 | 66 733 (59) | 66 811 (58) | 73 659 (58) | 93 336 (60) | 300 539 (59) |
| 21-50 | 42 375 (37) | 43 333 (38) | 48 315 (38) | 56 238 (36) | 190 261 (37) |
| >50 | 4246 (4) | 4682 (4) | 5955 (5) | 6764 (4) | 21 647 (4) |
| No of positive nodes†: | |||||
| 0 | 53 773 (47) | 63 095 (55) | 69 693 (54) | 101 898 (65) | 288 459 (56) |
| 1-3 | 41 169 (36) | 34 458 (30) | 39 543 (31) | 40 494 (26) | 155 664 (30) |
| 4-9 | 13 498 (12) | 12 034 (10) | 12 591 (10) | 9601 (6) | 47 724 (9) |
| ≥10 | 4914 (4) | 5239 (5) | 6102 (5) | 4345 (3) | 20 600 (4) |
| Tumour grade†: | |||||
| Low | 25 257 (22) | 23 427 (20) | 22 036 (17) | 26 738 (17) | 97 458 (19) |
| Medium | 50 361 (44) | 53 362 (46) | 61 618 (48) | 79 842 (51) | 245 183 (48) |
| High | 37 736 (33) | 38 037 (33) | 44 275 (35) | 49 758 (32) | 169 806 (33) |
| Oestrogen receptor status†: | |||||
| Positive | 86 965 (77) | 93 781 (82) | 106 485 (83) | 134 398 (86) | 421 629 (82) |
| Negative | 26 389 (23) | 21 045 (18) | 21 444 (17) | 21 940 (14) | 90 818 (18) |
| HER2 status†: | |||||
| Negative | - | - | - | 135 875 (87) | 135 875 (27) |
| Positive | - | - | - | 20 463 (13) | 20 463 (4) |
| Before 2010 | 113 354 (100) | 114 826 (100) | 127 929 (100) | - | 356 109 (69) |
| Breast cancer laterality†: | |||||
| Left | 58 708 (52) | 59 093 (51) | 65 830 (51) | 80 276 (51) | 263 907 (51) |
| Right | 54 646 (48) | 55 733 (49) | 62 099 (49) | 76 062 (49) | 248 540 (49) |
| Index of multiple deprivation: | |||||
| <20% (least deprived) | 25 386 (22) | 26 034 (23) | 29 601 (23) | 37 027 (24) | 118 048 (23) |
| 20-39% | 25 389 (22) | 26 205 (23) | 29 360 (23) | 36 112 (23) | 117 066 (23) |
| 40-59% | 23 854 (21) | 24 143 (21) | 26 987 (21) | 32 825 (21) | 107 809 (21) |
| 60-79% | 21 148 (19) | 21 131 (18) | 23 273 (18) | 27 985 (18) | 93 537 (18) |
| ≥80% (most deprived) | 17 577 (16) | 17 313 (15) | 18 708 (15) | 22 389 (14) | 75 987 (15) |
| Region of residence‡: | |||||
| Eastern | 12 195 (11) | 12 734 (11) | 13 623 (11) | 18 238 (12) | 56 790 (11) |
| North West | 16 270 (14) | 15 936 (14) | 17 514 (14) | 20 280 (13) | 70 000 (14) |
| Northern and Yorkshire | 14 095 (12) | 15 521 (14) | 17 039 (13) | 20 275 (13) | 66 930 (13) |
| Oxford | 7776 (7) | 6643 (6) | 7149 (6) | 9374 (6) | 30 942 (6) |
| South West | 18 712 (17) | 17 589 (15) | 20 222 (16) | 24 520 (16) | 81 043 (16) |
| Thames | 24 723 (22) | 23 093 (20) | 27 231 (21) | 32 564 (21) | 107 611 (21) |
| Trent | 5174 (5) | 10 455 (9) | 11 218 (9) | 15 109 (10) | 41 956 (8) |
| West Midlands | 14 409 (13) | 12 855 (11) | 13 933 (11) | 15 978 (10) | 57 175 (11) |
| End of follow-up (years from diagnosis): | |||||
| ≤1 | 3135 (3) | 2130 (2) | 1688 (1) | 1308 (1) | 8261 (2) |
| 1-2 | 5166 (5) | 3864 (3) | 3190 (2) | 2695 (2) | 14 915 (3) |
| 2-3 | 5216 (5) | 4057 (4) | 3579 (3) | 3122 (2) | 15 974 (3) |
| 3-4 | 5064 (4) | 4009 (3) | 3778 (3) | 3458 (2) | 16 309 (3) |
| 4-5 | 3959 (3) | 3573 (3) | 3200 (3) | 145 755 (93) | 156 487 (31) |
| 5-10 | 16 231 (14) | 14 874 (13) | 15 735 (12) | - | 46 840 (9) |
| 10-15 | 12 784 (11) | 13 497 (12) | 96 759 (76) | - | 123 040 (24) |
| 15-20 | 11 229 (10) | 68 822 (60) | - | - | 80 051 (16) |
| 20-21 | 50 570 (45) | - | - | - | 50 570 (10) |
HER2=human epidermal growth factor receptor 2 (data available only for period 2010-15).
*
Categories reflect eligibility for breast cancer screening programme (ie, 50-64 years for all calendar periods of diagnosis and 65-70 years from 2005). See table S3 for separate values according to screening status.
†
Some values were unknown in original data; values for these characteristics have been estimated using multiple imputation (see text S2 for details).
‡
Based on former cancer registry regions.